Amgen Kepivance To Launch In January; Additional Mucositis Trials Underway
Executive Summary
Amgen will launch the oral mucositis treatment Kepivance (palifermin) in late January following FDA approval Dec. 15
You may also be interested in...
MGI Saforis NDA To Be Based On Single Phase III Trial; Filing Planned For Q3
MGI Pharma expects to file an NDA for Saforis (l-glutamine oral suspension) for the treatment of oral mucositis based on the results of one Phase III trial and supportive earlier-phase trials
MGI Saforis NDA To Be Based On Single Phase III Trial; Filing Planned For Q3
MGI Pharma expects to file an NDA for Saforis (l-glutamine oral suspension) for the treatment of oral mucositis based on the results of one Phase III trial and supportive earlier-phase trials
Tarceva, Kepivance, And Macugen Approvals Are Quiet Milestones For FDA
Genentech/OSI's Tarceva, Amgen's Kepivance and Pfizer/Eyetech's Macugen are the first three products approved under the "continuous marketing application" pilot program